ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2016 - 2025)

ProQR Therapeutics' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $36.0 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 16.77% year-over-year to $36.0 million; the TTM figure through Dec 2025 stood at $36.0 million (down 16.77% YoY), while the FY2025 annual figure was $36.0 million, down 16.77% from the prior year.
• Total Non-Current Liabilities came in at $36.0 million for Q4 2025 at ProQR Therapeutics, down from $43.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $85.3 million in Q4 2022 to a low of $36.0 million in Q4 2025.
• A 5-year average of $62.1 million and a median of $67.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 106.91% in 2021 and plunged 35.43% in 2024, its largest moves.
• ProQR Therapeutics' Total Non-Current Liabilities stood at $78.7 million in 2021, then rose by 8.51% to $85.3 million in 2022, then retreated by 21.47% to $67.0 million in 2023, then tumbled by 35.43% to $43.3 million in 2024, then decreased by 16.77% to $36.0 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $36.0 million, $43.3 million, and $67.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison